Abstract: Compounds and compositions are provided that can inhibit microsomal prostaglandin E synthase-1 (mPGES-1). The compounds and compositions can reduce inflammation in a subject, such as inflammation caused by an inflammation disorder or symptoms thereof. Pharmaceutical compositions comprising the compound are also provided. Furthermore, methods are provided for reducing inflammation and/or inhibiting mPGES-1. The methods can comprise administering an effective amount of the composition to a subject.

Abstract: A compound and a method of detecting CLN3 are provided. The compound includes a heavy isotope labeled CLN3 proteotypic peptide. The method includes i) selecting a CLN3 proteotypic peptide that exhibits linear behavior in the mass spectrometer; ii) generating a stable isotope labeled standard; iii) spiking known amounts of the stable isotope labeled standard into a sample to form a spiked sample; iv) determining retention times and establishing calibration curves using the spiked sample; and v) detecting unlabeled selected CLN3 proteins in the sample.

Abstract: The present disclosure relates to compounds and compositions that inhibit the NLRP3 inflammasome, for example, a compound according to formula I wherein R1 is C1-4 alkyl; and R2 is H or C1-4 alkyl, provided that when R2 is H. R1 is not CH3. Also disclosed are methods for treating multiple sclerosis using the compounds and compositions.

Abstract: Unique compounds useful for inhibiting a proteasome in a cell, pharmaceutical compositions and methods of their use are provided herein.

Abstract: The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.

Abstract: The present invention provides a method for increasing the sucrose ester content of a tobacco plant or tobacco cell culture, the method comprising modifying said tobacco plant or tobacco cell culture by inhibiting the activity or expression of a diterpene synthesis gene. The present invention also provides for the use of a diterpene synthesis gene for increasing the sucrose ester content of a tobacco plant or tobacco cell culture, as well as tobacco cells, tobacco plants, tobacco plant propagation materials, harvested leaves, processed tobaccos, or tobacco products obtainable in accordance with the invention.

Abstract: Disclosed are small molecule PTPRD inhibitors and uses thereof. Methods of using the PTPRD inhibitors include methods of treating, preventing, or delaying the progression of a disorder responsive to PTPRD inhibition, including for example nicotine dependence, addiction, obesity, metabolic syndrome, and substance-use disorders such as stimulant-use disorders and opioid-use disorders.

Abstract: Methods of treating or reducing risk of aneurysm, reducing cardiovascular risk, reducing serum cholesterol, reducing serum triglycerides, and/or reducing atherosclerotic plague in a subject involve administering to the subject an effective amount of a 5HT3R antagonist.

Abstract: A composition and method for treating a subject following myocardial infarction are provided. The composition includes a non-PEGylated liposome. The method includes administering a non-PEGylated liposome to a subject in need thereof following myocardial infarction.

Abstract: A surgical skills training model has an elongated body including muscle, fascia, subcutaneous tissue, connective tissue and skin mimicking layers. The fascia and connective tissue layer are made from a material having a stretch direction that is aligned with a longitudinal axis of the muscle layer and the body of the model.

Abstract: Disclosed herein are high Tm RNA nanostructures that can be composed of one or more modules or motifs to build RNA nanostructures with or without layers. The RNA nanostructures can have a core domain and three or more double-stranded arms and formulations thereof to conjugate high copy numbers of therapeutics, pH responsive or enzyme cleavable drug cargo. Also described herein is a design strategy for generation of synthetic RNA oligonucleotides that can self assemble into highly thermostable RNA structures. Also described herein are uses of the RNA nanostructures described herein.

Abstract: A quality assurance device for a medical accelerator includes a housing having an inner radioluminescent layer adapted to provide a visual indication when contacted with invisible radiation generated by the medical accelerator. In addition, the quality assurance device includes one or more cameras located within the housing and adapted to image the inner radioluminescent layer of the housing including the visual indication.

Abstract: The presently-disclosed subject matter relates to an artificial RNA nanostructure and method of use thereof. In particular, the presently-disclosed subject matter relates to RNA nanoparticles and RNA dendrimers, and methods of disease diagnosis and treatments using the RNA nanostructure and RNA dendrimers.

Abstract: A hybrid post-combustion carbon dioxide capture system for capturing carbon dioxide from a flue gas includes a compressor adapted to produce a compressed flue gas stream, a membrane-based carbon dioxide separation unit configured to receive a first portion of the compressed flue gas stream from the compressor, and an aqueous-based carbon dioxide capture unit configured to receive a second portion of the compressed flue gas stream from the compressor whereby the compressed flue gas stream is processed in parallel by the membrane-based carbon dioxide separation unit and the aqueous-based carbon dioxide capture unit.

Abstract: Methods for detecting and extracting plastic contaminants within a water sample, which involve introducing the water sample to a hydrophobic deep eutectic solvent, are provided.

Abstract: A method of making curcuminoids in a mammalian cell. The method of making a curcuminoid in a mammalian cell includes expressing one or more enzymes in the mammalian cell, the enzymes being selected from the group consisting of tyrosine ammonia lyase (TAL), 4-coumaroyl-CoA ligase (4CL1), curcuminoid synthase (CUS), diketide-CoA synthase (DCS), curcumin synthase (CURS1), 4-coumarate 3-hydroxylase (C3H), caffeoyl-CoA 3-O-methyltransferase (CCoAMT), and acetyl-CoA carboxylase (ACC). The expressing of the one or more enzymes converts a starting material, such as tyrosine or ferulic acid, to the curcuminoid. Also provided herein are therapeutic uses for the curcuminoid made in a mammalian cell.

Abstract: Derivatized malachite green leuco dyes for use in radio-chromic systems are described. The dyes have the following structure: in which Ar is a substituted phenyl or thiophene ring in which at least one substitution of the Ar ring is not ortho to the bond between the ring and the linking carbon, and in which R1, R2, R3, and R4 are independently selected from methyl, alkyl, or alkyl halide. The systems include the dyes in conjunction with an activator, e.g., a halogenated activator, and a carrier, e.g., a fluid carrier or an encapsulating polymeric matrix.

Abstract: A quality assurance device for a medical accelerator includes a housing having an inner radioluminescent layer adapted to provide a visual indication when contacted with invisible radiation generated by the medical accelerator. In addition, the quality assurance device includes one or more passive optical components within the housing adapted to deliver an image of the inner radioluminescent layer of the housing including the visual indication to one or more cameras located outside of the housing.

Abstract: Therapeutic uses P2X7 inhibition and inhibition of IRAK1 and/or IRAK4, methods protecting a cell, and screening methods for identifying inhibitors are described herein.

Abstract: An apparatus for removing an acid gas from a feed gas stream includes an absorber and an electrochemical regenerator. The absorber is adapted for separating the acid gas from the feed gas feed stream using a lean carbon capture solvent. The electrochemical regenerator is connected to the absorber and adapted for (a) regenerating the carbon capture solvent and (b) generating hydrogen gas. A method for removing acid gas from a feed gas stream includes steps of separating, delivering, releasing, generating and returning.